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Abstract 
Immunisation of female guinea pigs with a chimeric peptide consisting of variable 
domain IV (VDIV) and a region known as GP8 from the major outer membrane protein 
(MOMP) of Chlamydophila caviae, formerly Chlamydia psittaci Guinea Pig Inclusion 
Conjunctivitis (GPIC) strain, was performed to assess whether humoral immune 
responses could be elicited in the reproductive tracts of immunised animals. The 
C.caviae strain is able to cause a sexually transmitted infection in the guinea pig that 
closely parallels C. trachomatis infections in humans. The best anti-VDIV antibody 
response in vaginal secretions was achieved by intraperitoneal priming with subsequent 
intravaginal boosting (P<0.001). Dot-blot analyses of vaginal secretions confirmed that 
these anti-VDIV antibodies, produced against a linear peptide, were able to recognise 
and bind to whole conformational C. caviae elementary bodies. Following live 
intravaginal challenge with C. caviae, a significant reduction in the intensity (P=0.01) 
and an apparent reduction in the duration of the infection was evident between the 
guinea pigs immunised with VDIV-GP8 and non-immunised controls. 
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Introduction 
Chlamydia trachomatis is an obligate, intracellular, gram negative pathogen which 
causes infections at the mucosal surfaces of humans. Chlamydial infection of the 
human reproductive tract is of particular concern, as C. trachomatis is implicated in 
the development of pelvic inflammatory disease (PID) and salpingitis with 
subsequent infertility in females1. Such damage is thought to occur as a result of 
deleterious host (hypersensitivity) responses against, as-yet, undefined chlamydial 
epitopes 2.  
The development of a vaccine for sexually transmitted disease caused by  
C. trachomatis presents unique challenges.  Delivery of whole C. trachomatis to 
humanshas been shown to induce partial immunity against genital infection3.  
Unfortunately, whole chlamydial vaccines have also been shown to cause 
deleterious hypersensitivity responses in the host, resulting in more severe pathology 
compared to the natural disease 4. As a result of these findings, research into 
chlamydial vaccines has centred on the development of subunit vaccines which 
contain protective epitopes, but exclude epitopes which produce pathological 
responses in the host.    
The guinea pig model of genital infection with GPIC (Guinea Pig Inclusion 
Conjunctivitis strain of C.psittaci; recently re-named Chlamydophila.caviae 5) was 
chosen since this organism naturally infects the reproductive tract of guinea pigs and 
causes a disease which closely resembles C.trachomatis infections in humans. The 
similarities between the guinea pig and human chlamydial reproductive diseases 
include the mode of transmission 6, vaginal target tissues 7, histopathology, 
  
immunology and infection sequelae, including the occurrence of salpingitis and 
infertility 8.  
The chlamydial antigen chosen for this investigation was a chimeric linear peptide 
representing two distinct regions (variable domain IV - VDIV and a region known as 
GP8) of the major outer membrane protein (MOMP) of C.psittaci GPIC. The 
immunogenicity of these MOMP regions in GPIC has not previously been 
investigated, however, corresponding regions in C. trachomatis are known to elicit 
both B- and T- cell immune responses, with VDIV the target of antibody production, 
and GP8 providing T-cell help 9. 
By using the guinea pig model of genital infection with the synthetic antigenic 
peptide, VDIV-GP8, we were able to examine both the immunogenicity of the VDIV 
and GP8 antigens and also to determine whether or not immunisation provides 
protective immunity in vivo against infection with the naturally occurring chlamydial 
agent. 
  
Materials and methods 
Experimental Animals  
Sexually mature (600-700g), female, random outbred English short-haired (ROES) 
guinea pigs (Institute of Medical and Veterinary Sciences, Adelaide, SA, Australia), 
were housed individually in filter-top mini-isolators in a room kept at 21°C on a 
12hour light and 12 hour dark cycle. Animals were fed standard guinea pig pellets 
(Norco Co-operative, Lismore, NSW) and tap water supplemented with 4mg/20L 
ascorbic acid (Melrose Laboratories, VIC) ad libitum. All work undertaken complied 
with relevant Queensland University of Technology Biomedical Ethics Committee 
guidelines (BEC # 875/1A). 
Peptides 
The oligopeptides (synthesised and conjugated by Chiron Mimotopes, Melbourne, 
VIC, Australia) were provided at 70% purity and were quantitated by Mass Spectral 
analysis (Perkin-Elmer Sciex API III) and also confirmed as containing the target 
peptide by MS analysis. 
The synthesised peptide GP8 contained a predicted TH-cell epitope (Roger Rank, 
pers.comm.) and corresponded to GPIC MOMP residues 106-130 
(WDRFDVFCTLGASNGYLKANAAAFN). Peptide VDIV corresponded to GPIC 
MOMP residues 285-315 (PTAILNLTTWNPTLLGEATTINTGAKYADQL).  The VDIV 
and GP8 oligopeptides were synthesised individually and a mixture of the two 
peptides was conjugated at both termini (GP8 at the amino terminus and VDIV at the 
carboxy terminus) to the carrier molecule Keyhole Limpet Haemocyanin (KLH). The 
synthetic, conjugated oligopeptide (i.e. VDIV and GP8 peptides linked to KLH) was 
  
used for all immunisations in this study and is, hereafter, referred to as VDIV-GP8 
peptide. 
Cell culture and detection of Chlamydia 
C. psittaci GPIC was cultured in McCoy cell monolayers 10 using Dulbecco’s modified 
Eagle’s medium (DMEM) (Commonwealth Serum Laboratories, Australia), 
supplemented with 10% fetal calf serum (Gibco/BRL). GPIC inoculum containing 2 x 
106 inclusion forming units/mL (IFU/mL) was added onto 1x107 McCoy cell 
monolayers before centrifugation at 850g for 1 hour at room temperature.  The 
infected cells were incubated (36°C/5%CO2) for 2 hours before the addition of 5 mL 
DMEM with 1μg/mL cyclohexamide (Sigma Biochemicals).  The media was replaced 
(DMEM with 1μg/mL cyclohexamide) at 24 hours post-infection and the level of 
infection analysed by fluorescent monoclonal antibody staining using an FITC-
conjugated monoclonal antibody against chlamydial lipopolysaccharide (Chlamydia-
cel LPS kit, Cellabs Diagnostics). Cultures were frozen at -80°C, diluted 1:1 in 
sucrose-phosphate-glutamate (SPG) buffer until use. C. caviae elementary bodies 
(EBs) were purified on a renografin gradient 11 .   
Specimen Collection 
The guinea pigs were anaesthetised with 0.75-1.0 mL/kg Hypnorm by intraperitoneal 
injection prior to collection of serum and vaginal secretions.  Vaginal smears were 
collected by insertion of a sterile cotton swab (Disposable Products, S.A) 
approximately 2cm into the vagina with vigorous rotation against the vaginal wall and 
cytological smears rolled onto glass before immediate fixation with Cytospray (SEA 
Trading Pty.Ltd., QLD, Australia). Smears taken for assessment of chlamydophila 
infection were air dried and fixed in methanol for 10 minutes. Vaginal secretions were 
  
collected using surgical sponges (Weck-cel, Xomed-Treace, Florida, USA), cut to 
form ‘wicks’, inserted into the guinea pig vagina for 0.5-2.0 hours12 before removal 
and immediate storage at -20°C.  Antibodies for immunoassays were eluted from the 
‘wicks’ by the addition of 1mL PBS containing 1% Tween-20 and 5% sodium azide 
(PBS-T 5% NaN3) followed by centrifugation at 15,000g for 5 minutes at 4°. The 
supernatants were analysed immediately, or stored at -80°C (for less than 4 weeks) 
before analysis.  Antibodies for in vitro neutralisation were eluted from the ‘wicks’ in 
1mL sterile PBS.  
Blood was collected into lithium-heparin tubes (Becton Dickinson Vacutainer 
Systems) from the lateral saphenous leg vein of the guinea pigs using a 23G 
needle13 and serum recovered following centrifugation at 200g for 5 minutes at 4°C 
before storage at -20°C. 
Peptide Immunisation and challenge with live GPIC 
Five animals were immunised with VDIV-GP8 peptide by intraperitoneal priming and 
intravaginal boosting (test group), while another five were immunised with carrier and 
adjuvant only (control group).  Each immunisation with the conjugate contained 
500μg VDIV-GP8 peptide in phosphate buffered saline (PBS), pH 7.4. Freund’s 
complete and incomplete adjuvants (Calbiochem Corporation) (50% v/v) were used 
for intraperitoneal priming and lysophosphatidyl glycerol (Sigma Biochemicals) (0.5% 
w/v) was used as the mucosal adjuvant for intravaginal immunisations 14. 
Intravaginal immunisations were given to guinea pigs under xylazine/ketamine 
anaesthesia (5-10mg/kg xylazine and 60mg/kg ketamine i.p.) at a non-oestrus stage 
of the guinea pig oestrus cycle, as determined by Papanicolaou staining of vaginal 
smears. Following intravaginal delivery of the peptide and LPG adjuvant with a 
  
micropipette, the vaginal opening was plugged with cotton wool saturated in sterile 
PBS to prevent inoculum leakage and uptake into the plug.   
Thirty-eight days following immunisation (either with VDIV-GP8 peptide or negative 
control preparation) all 10 animals were challenged intravaginally with live GPIC. 
Serum and vaginal secretions were collected from animals prior to, and weekly for 
nine weeks following, immunisation.  Vaginal smears were collected twice weekly 
post infection. All individual secretion samples were assayed by ELISA (in duplicate, 
at two different dilutions) both for anti-VDIV IgG and for IgA levels.  
For live challenge experiments, the animals were inoculated intravaginally at day 38 
post-immunisation with 0.05mL of 1 x 107 GPIC inclusion forming units (IFU)/mL, 
according to the method used for intravaginal peptide delivery.  Vaginal smears were 
stained using fluorescent monoclonal antibodies (described above). Vaginal smears 
were assessed for percentage of infection and size of inclusions.  
Dot Blot Antibody Analyses 
For the analysis of antibodies in sera, unconjugated VDIV peptide, purified GPIC 
elementary bodies (EBs) and whole McCoy cells were diluted in PBS and applied 
independently to nitrocellulose membranes using a vacuum-blot apparatus (Biodot, 
Biorad) to deliver 2μg per dot for each antigen used.  Membranes were blocked 
overnight in blocking solution (3% skim milk in Tris buffered saline, pH 7.4 TBS) 
before washing 3 times with TBS and once with TBS/ 0.5% Tween-20 (TBS-T).  For 
the analysis of antibodies in vaginal secretions, secretions were diluted to 
0.125mg/ml of protein (DC Protein assay, Biorad) and control sera diluted 1:5 in 
blocking solution before incubation with the membrane and subsequent washing (as 
above). Horse radish peroxidase (HRP) conjugate (rabbit anti-guinea pig IgG-HRP) 
(ICN Biomedicals) was diluted 1:1000 in TBS before incubation with dot blots for 1 
  
hour and washing (as above) for detection of IgG antibodies. Analysis of IgA 
antibodies in vaginal secretions was achieved using rabbit anti-guinea pig IgA 
primary antibody and goat anti-rabbit HRP conjugate as secondary antibody. The 
blots were visualised using solubilised 10mg 3,3-diaminobenzidine tetrahydrochloride 
(DAB) substrate tablets (Sigma Immunochemicals). 
 
ELISA Analysis 
Briefly, 96 well microplates (Maxisorp, Nalge-Nunc International) were coated at 4°C 
overnight with 0.75μg/well unconjugated VDIV peptide (diluted in PBS) before 
blocking overnight at 4°C with 100μl of 3% skim milk in PBS.  Vaginal secretions 
were tested at dilutions of 1:25 and 1:250, with each plate also incorporating 
standard dilutions (1:10 - 1:5000) of untitrated positive anti-VDIV secretions, the 
absorbances of which were used to generate standard curves. The antibodies used 
for detection of IgG and IgA were identical to those used in the dot blots.  Plates 
were washed 5 times in PBS containing 0.5% Tween-20 (PBS-T) on an ELISA plate 
washer (Murex Diagnostics) following each incubation. The HRP substrate used for 
colorimetric detection of antibodies was K-blue (ELISA technologies). Reactions 
were stopped at 3 minutes with an equal volume of 3N HCl and absorbances read at 
650nm against a blank of 450nm on an ELISA plate reader (Biomek, Beckman).  
In Vitro Neutralisation Assays 
According to the method of Su and Caldwell 9  1 x 105 McCoy cells were seeded onto 
glass coverslips in 24 well microplates (Nalge-Nunc International) and incubated at 
36°C/5%CO2/24hr.  Two-fold dilutions of vaginal secretions were made in DMEM, 
and incubated (36°C/5%CO2/24hr) for 30 minutes with an equal volume of DMEM 
  
containing 5 x 106 IFU/mL GPIC before 0.25 mL of each mixture was inoculated onto 
the McCoy cell monolayers. Standard culture methods as described previously were 
used, except that the cells were washed with PBS at 24 hours, before the addition of 
DMEM. The cultures were fixed in methanol at 42 hours post-infection and coverslips 
stained immediately for identification of chlamydophila inclusions.  Approximately 100 
cells per coverslip were counted and the percentages of infected cells calculated. 
Levels of chlamydophila infection were compared between two sets of samples: 
pooled pre-immune (control, day 0) and pooled post-immune (test, day 37) 
secretions. Neutralisation was defined as a 50% reduction in the percentage of 
infected cells present in the test assay when compared to the control assay at the 
same dilution 9.  The neutralising titre was defined as the reciprocal of the highest 
dilution of the post-immune sample that exhibited neutralisation.   
Results 
Intraperitoneal and intravaginal immunisation with VDIV-GP8 peptide induces 
anti-VDIV antibody responses in vaginal secretions 
Preliminary trials to determine the best route for VDIV-GP8 peptide immunization 
investigated intravaginal (i.vag) immunisation for priming and boosting (i.vag/i.vag) 
and a combination of intraperitoneal(ip)/ intravaginal(i.vag) immunisation routes. 
Results showed that i.p immunisation followed 3 weeks later by i.vag antigen delivery 
produced the best anti-VDIV IgG and antibody responses in vaginal secretions of  
immunised guineapigs (Figure 1) (P<0.001). The wide error bars in Figure 1 are 
explained by the fact that the animals in the study are Random outbred guinea pigs. 
Anti-VDIV IgG (low amounts) and IgA antibodies in secretions were evident at day 
14, but increased dramatically following an intravaginal boost with VDIV-GP8 peptide 
  
at day 21. The combination of intraperitoneal priming followed by intravaginal 
boosting with the synthetic peptide was, therefore, chosen as the route of 
immunisation for subsequent experiments. 
Immunisation with linear VDIV-GP8 peptide induces antibodies able to bind the 
epitope on native MOMP and neutralise infection in vitro 
Dot-blots were used to determine whether or not anti-VDIV antibodies in vaginal 
secretions (produced against linear peptide VDIV-GP8) were able to bind to the 
native MOMP on whole EB’s (Figure 2). The test assays were done using pooled 
secretions of two animals that showed high amounts of vaginal anti-VDIV IgG and 
IgA antibodies following peptide immunisation but prior to live C.caviae challenge.  
The same amount of ‘secretion’ protein (wick eluate) was added for test and control 
specimens to allow the intensity of the dots to be used as a direct measure of 
antibody concentration.  The reactivity of test sera compared to the negative control 
(the same animals pre-immunisation) indicates that IgG antibodies produced in 
response to immunisation with linear VDIV peptide bound to the conformational VDIV 
epitope on whole EBs.  Similar results were obtained with IgA dot blots although 
reactions were much weaker than those seen on the IgG blots (data not shown).   
In vitro neutralisation assays were undertaken to determine whether or not anti-VDIV 
antibodies produced in guinea pig vaginal secretions could prevent GPIC infection of 
McCoy cells in a cell culture system. The assays were done using the same pooled 
secretions as those used in the western blot (Fig. 2).  Assays using the two sets of 
vaginal secretion samples (pooled pre-immune and pooled post-immune secretions) 
showed neutralisation defined as a 50% reduction in the percentage of infected cells 
present in the test assay, when compared to the control assay at the same dilution.  
At a 1:20 dilution of post-immune secretions there was at least 50% reduction in the 
  
percentage of infected cells compared to the 1:20 dilution of the pre-immune 
secretions (Figure 3). 
Figure 3 is a plot of the percentage of McCoy cells infected with C. caviae against 
dilutions (1/20-1/320) of secretions both for pre- and for post-immune samples.  
Antibodies in post-immune secretions show neutralising activity not only at the 1:20 
dilution, but also at 1:40 and 1:80 dilutions, as evidenced by the separation of the two 
lines (pre-immune vs. post immune secretions) in Figure 3. The neutralising titre was 
found to be 20 which reflects the method used to extract antibodies from the vaginal 
wicks which dilutes the secretions. It was also noted that the activity of the serum did 
not titrate until a dilution of 1/80 although the reasons for this are presently unclear 
and require further investigation. 
Protection of immunised guinea pigs to live challenge does not correlate 
directly to antibody levels 
A challenge experiment was undertaken to determine whether i.p/i.vag immunisation 
with the linear VDIV-GP8 peptide could provide protection against GPIC infection of 
guinea pigs in vivo.   On the day prior to challenge vaginal secretions were collected 
and analysed by ELISA for anti-VDIV IgG and IgA antibodies.  Three out of five of the 
immunised animals showed anti-VDIV IgG responses, whilst only one guinea pig  
exhibited an IgA response.  None of the control animals showed antibody responses 
against VDIV (data not shown). 
When challenged i.vag with a moderate level of live GPIC, a degree of protection (as 
evidenced by a 15-20% reduced parasite load) was found in the immunised group 
(Figure 4). This observed reduction in parasite load was present immediately 
following challenge and persisted until the infection was cleared.  While this reduction 
in parasite load was modest (5-15%) it was significant (P=0.01).  
  
There was an apparent reduction in the intensity of infection in immunised when 
compared to the non-immunised animals over the full 26 days following challenge 
(Figure 4).  This apparent reduction is confirmed by statistical analysis.  Using a two 
factor analysis of variance test 15 with repeated measures on one factor (time) there 
was a significant (P = 0.01) decrease in the intensity of infection in the immunised 
group when compared with non-immunised controls.  These results indicate that 
although immunisation of guinea pigs i.p./i.vag with the VDIV-GP8 peptide did not 
completely block initial intravaginal infection with C. caviae , partial protection, 
represented as a reduced level of infection over the course of the experiment, was 
evident in immunised animals.   
Four out of five immunised guinea pigs cleared the infection within the course of the 
experiment, in comparison to only one of five non-immunised animals (data not 
shown). There was an apparent inverse correlation between pre-challenge anti-VDIV 
secretion antibody levels and the duration of infection.  For example, the immunised 
animal which recovered most quickly from the challenge (day 18) showed no anti-
VDIV antibody responses in the pre-challenge secretion collection (data not shown).  
Conversely, the immunised guinea pig that was unable to clear infection in the 
experimental period showed high levels of IgG and was the only animal tested that 
showed any anti-VDIV IgA response in pre-challenge vaginal secretions (data not 
shown).  
Live GPIC challenge of immunised animals did result in moderate protection.There 
was, however, no correlation between pre-challenge anti-VDIV IgG and IgA levels in 
secretions and initial levels of infection (day7 post infection) seen in the animals 
(r2=0.04, r2.<0.01 respectively). 
  
Discussion 
Since C. trachomatis enters the body via the reproductive tract mucosa, the ability of 
a vaccine to elicit strong immune responses in the vagina is an important indicator of 
protection against infection with this organism. The hypothesis that local (vaginal) 
antibody production against chlamydia is at least partially protective was derived 
from a study in which C.caviae infection of the guinea pig genital tract was prolonged 
by estradiol administration to the animals.  The prolongation of infection correlated 
with a delay in the production of anti-GPIC antibodies in secretions that occurred in 
the presence of normal (non-delayed) serum antibody responses. Resolution of the 
infection was associated with the appearance of both IgG and IgA in genital 
secretions. 16 GPIC infection of guinea pigs is, therefore, a good model to use for 
studying Pelvic Inflammatory Disease caused by C.trachomatis in humans. 
Several investigators have measured serum antibody responses following parenteral 
delivery of various C. trachomatis MOMP subunits to mice 9,  were no studies on the 
ability of synthetic chlamydial peptides to elicit humoral responses in the vagina of 
immunised hosts, or of immune responses against chlamydial peptide delivered to 
animals by anything other than parenteral routes.  The purpose of this study was, 
therefore, to investigate whether combination systemic/mucosal (i.p/i.vag) 
immunisation of female guinea pigs with a chimeric chlamydial peptide could elicit 
humoral immune responses in the reproductive tracts of immunised animals. Our 
finding that  i.p./i.vag delivery of  a chimeric peptide to guinea pigs can elicit  specific 
anti-chlamydophila responses in vaginal secretions of immunised animals is, 
therefore, important towards the progress of vaccination against this mucosal 
pathogen. 
  
Two important questions must be addressed when attempting to immunise against 
pathogens with a synthetic linear peptide.  Firstly, will the linear amino acid sequence 
be recognised as an immune epitope by the host and result in activation of B and T 
lymphocytes?  Secondly, in the case of B-lymphocytes, will antibodies produced 
against the linear epitope be able to recognise and bind to the native epitope upon 
challenge? 
Although the amino acid sequences for the variable domains the C.caviae agent 
were known, and various B- and T-cell epitopes had been predicted, the properties of 
antibody directed against the variable domains of C. caviae previously were 
unknown.  It was an important finding of this study, therefore, that antibodies in 
vaginal secretions directed against the linear VDIV-GP8 peptide are able to bind to 
whole C. caviae elementary bodies (Figure 2).  This is the first step in establishing 
the potential of antibody to protect against chlamydial infectivity. 
Previous studies have shown that antibodies produced in serum against C. 
trachomatis VDIV are able to neutralise the infectivity of C. trachomatis in cell  
culture 11 . However, it has also been shown that high serum IgG antibody levels do 
not protect against chlamydial genital infections in vivo .  In our investigation, we 
immunised animals that subsequently produced anti-VDIV antibodies at the site of 
infection and another new finding was that these antibodies provided neutralising 
activity against C. caviae EB’s in a McCoy cell system.  
Results of previous chalmydial challenge experiments using guinea pigs have 
indicated that parenteral and oral immunisation with whole inactivated EBs of 
C.caviae 15 and parenteral immunisation with the entire MOMP protein 20 were able to 
induce partial protection against subsequent infection.  Partial protection in these 
cases was seen as a statistically significant reduction in the duration and/or the 
  
intensity of infection.  Non-replicating antigens, including whole,inactivated 
Chlamydia have not, however, been reported to induce complete protection upon 
challenge in the guinea pig 20.  Our results showed that a chimeric peptide antigen 
delivered ip/ivag to guinea pigs induced specific anti-chlamydial antibodies in the 
vagina of immunised animals and the antibodies were neutralising in vitro.    
Interestingly, the partial protection seen did not correlate with pre-challenge antibody 
levels in vaginal secretions.  The anomalous fact that the guinea pig with the highest 
anti-VDIV response cleared the challenge infection last, and that a guinea pig with no 
response at all recovered first indicates that the protection observed in this study 
may be cell mediated in nature.   
Several studies in recent years have highlighted to importance of T-cells 21, 22 and 
associated cytokines 23,24 in resolution of infection and prevention of re-infection with 
chlamydial agents.  The role of cellular immunity in response to the peptides in this 
study will be a focus of future research.    
It is encouraging that we are able to induce partial protection against genital infection 
with the GPIC agent, C. caviae.  Of particular importance is the fact that the 
protection in this study was induced by vaccination with a peptide antigen.  Indeed, 
the partial reduction in parasite load that we have observed in our study maybe 
useful for vaccination leading possibly to reduced transmission and /or reduced 
pathology in infected hosts. 
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Figure 1 
ELISA showing levels of anti-VDIV antibodies in vaginal secretions of guinea pigs 
after immunisation with VDIV-GP8 peptide either by: i.p (priming)/i.vag. (boosting) or 
by the i.vag/i.vag. routes (n=5). Anti-VDIV IgG (Fig 1a) and IgA (Fig 1b) levels are 
expressed as x-fold increases over background levels exhibited in the non-
immunised (control) samples. The baseline OD value (negative cutoff) was an 
Absorbance value of 0.2 units.  Individual results from each animal were grouped 
according to the immunisation route used. The mean anti-VDIV IgG and IgA levels in 
vaginal secretions and the standard deviations for each group were determined at 
each of the sample collection time points. Arrows indicate the time of  priming and 
boosting with peptide (once for i.p delivery of peptide, three immunisations/two days 
apart for i.vag. delivery) 
 
 
  
 
Figure 2 
Dot blots showing reactions of IgG in vaginal secretions against GPIC EBs, McCoy 
cells and VDIV (in duplicate). Secretions used were pooled from two animals in the 
chalmydia challenge experiment and standardised with respect to total protein 
contained in the wicks. Samples used to probe the blots were (1) post-challenge 
(positive control), (2) pre-immune (negative control) and  (3) post-immunisation (test) 
secretions. 
 
 
 
  
 
Figure 3 
In vitro neutralisation assays using pooled guinea pig vaginal secretions.  The 
secretions used were taken from two animals and were collected either pre-
immunisation (control) or at day 37 post-immunisation (test) with VDIV-GP8 peptide. 
Secretions were standardised with respect to total protein concentration. 
 
  
Figure 4  
Chlamydia challenge infection of animals immunised i.p(priming)/i.vag.(boosting) with 
VDIV-GP8 peptide, compared with  non-immunised controls (which received carrier 
and adjuvant only). Levels of infection were determined as follows: Individual data 
from each collection (pre-challenge, days 7, 11, 14, 18, 21, 26 post-challenge) was 
grouped (either immunised or non-immunised) and for each smear, three oil-
immersion fields were examined and the percentage of infected cells per field 
calculated. Levels of infection are presented as the mean level of infection per group 
of 5 animals at each sample collection point. Error bars indicate one standard 
deviation from the mean. 
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